novo nordisk patent semaglutide Semaglutide's expires today. What does it mean for patients, pharma players and Nordisk? Ozempic's patent problem: how Novo

As we await prospective data, clinical practice should consider the difference between abrupt stop vs gradual taper when counseling patients about expectations after therapy

Regulators will evaluate TRANSCEND-T2D trial data and assess advantages and risks

Our board-certified providers specialize in personalized, science-based approach to help patients lose weight

Zentralbl Chir

doi: 10.3389/fendo.2026.1788698 Received 15 January 2026 Revised 30 January 2026 Accepted 13 February 2026 Published 03 March 2026 Volume 17 - 2026 Edited by Ploutarchos Tzoulis, University College London, United Kingdom Reviewed by Lai San Tham, Eli Lilly, United States Updates Copyright 2026 Alhazmi and le Roux

Improper storage can lead to reduced potency, making the medication less effective